President Trump Went on a Palantir Buying Spree. Is It Time for You to Do the Same?

Palantir is being assessed at $133/share with a consensus 12-month target of $188, but the article concludes the stock is a Hold because valuation is extremely rich at 150x earnings and 66x sales. Fundamentals remain strong, including a 145% Rule of 40, 85% YoY Q1 revenue growth, and continued beats, yet insider selling by Peter Thiel and others plus potential multiple compression keep the risk/reward balanced. The stock is down over 20% year-to-date and only up 6% over the past year, suggesting sentiment is mixed despite bullish AI and U.S. commercial growth narratives.

Analysis

PLTR’s setup is less a fundamentals question than a duration question: the market is forcing investors to pay today for a revenue stream whose durability will only be tested over multiple quarters. That creates a sharp asymmetry — if commercial expansion keeps compounding, the valuation can stay irrational longer than shorts can stay solvent, but if growth merely normalizes, the multiple can re-rate faster than the business can backfill it. The second-order issue is that any deceleration will be interpreted not as “still strong” but as evidence the premium AI-software cohort has already pulled forward several years of upside.

The real competitive signal is that PLTR is not just competing with traditional enterprise software; it is competing with internal data-platform budgets and consulting spend. If its land-and-expand motion is working, the losers are legacy integrators and vertical SaaS vendors whose budgets get displaced by a centralized AI operating layer. But that also means the company is exposed to procurement fatigue: once a few marquee customers slow expansion, the narrative can flip from platform winner to over-earnest vendor selling expensive experimentation.

Catalysts are concentrated in the next 1-2 quarters, not years. The key risk is not a total business break, but a small miss against extreme expectations: even a modest downgrade in U.S. commercial growth or remaining deal value can trigger multiple compression because the stock trades with little margin for error. Insider selling matters mainly as a signal that management understands the stock’s reflexivity; it does not predict fundamentals, but it can amplify selloffs if the print disappoints.

The consensus is underestimating how fragile the market’s tolerance is for ‘good but not absurd’ growth. The move may be overdone on the downside if investors are anchoring to peak multiples without recognizing the business still deserves a premium, but it is underdone on the upside only if AIP continues to shorten sales cycles while expansion rates stay exceptional. In other words, this is a volatility trade more than a directional one until Q2 confirms whether the flywheel is still accelerating.

Key Decisions for Investors

• Stay neutral-to-underweight PLTR into Q2 earnings; the risk/reward is poor for cash equity buyers here because a 5-10% revenue miss or softer commercial expansion could trigger 15-25% multiple compression.
• Buy PLTR put spreads 30-60 days out if the stock rallies back toward the prior high zone; define risk tightly and use the premium expansion to express downside on any post-earnings re-rating.
• If long-term bullish, wait for a 10-15% pullback and a confirmed Q2 beat/raise before initiating a starter long; that improves the asymmetry materially versus chasing at a triple-digit sales multiple.
• Pair trade: long a profitable AI infrastructure beneficiary with lower multiple sensitivity against short PLTR to isolate the ‘AI spend’ theme while neutralizing broad sector beta; this helps if AI capex persists but software premium compresses.
• Use a tactical long only on a clean post-earnings gap higher with raised guidance; otherwise treat PLTR as a momentum name with event risk, not a compounding core position.